Sarepta Therapeutics (SRPT) Accumulated Depreciation & Amortization (2011 - 2025)

Sarepta Therapeutics has reported Accumulated Depreciation & Amortization for 15 years, with the latest figure at $44.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 18.02% year-over-year to $44.5 million; the trailing twelve-month figure through Dec 2025 stood at $44.5 million (up 18.02% YoY), and the FY2025 full-year result was $44.5 million, up 18.02% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $44.5 million, up from $37.7 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $112.6 million in Q4 2021, with the low at $37.7 million in Q4 2024.
• Average Accumulated Depreciation & Amortization over 5 years is $56.2 million, with a median of $44.4 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization jumped 48.15% in 2021 and sank 62.83% in 2022.
• Tracing SRPT's Accumulated Depreciation & Amortization over 5 years: stood at $112.6 million in 2021, then slumped by 62.83% to $41.9 million in 2022, then increased by 6.05% to $44.4 million in 2023, then fell by 15.03% to $37.7 million in 2024, then rose by 18.02% to $44.5 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $44.5 million (Q4 2025), $37.7 million (Q4 2024), and $44.4 million (Q4 2023), per Business Quant data.

Peer Comparison